For The Public (SE) For The Public (IT) For The Public (DE) For The Public (FI) For The Public (CZ) For The Public (GR)
Home
About Us
Contact us
Consortium Description
Management
Research Partners
Partner Institutions
Research Activities
Summary
Dissemination of Knowledge
News
Contact
Press Releases
Events
FP6 Facts
For The Public
(Multilingual Content)
Project
News And Views
FP6

Research Activities Content : Dissemination of Knowledge
Posted by admin on Friday, October 03 @ 12:27:33 EEST (3964 reads)

Eliopoulos AG: "Make and Brake" in Cell Signaling. Science 2008, 321: 648-649.
Moschonas A, Kouraki M, Knox PG, Thymiakou E, Kardassis D & Eliopoulos AG: CD40 Induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1. Mol. Cell. Biol. 2008, 28: 6208-6222.
Loskog A and Eliopoulos AG: CD40 Ligand-based Cancer Therapy. In: New Gene Therapy & Cancer Research, 2008, pp 1-7. Ed. WB Gustaffsson, Nova Publishing Group.
Bauerschmitz GJ, Kangasniemi L, Pesonen S, Eriksson M, Porten M, Herrmann I, Virkkunen P, Tarkkanen M, Ranki T, Hakkarainen T, Kanerva A, Rein D & Hemminki A. Tissue specific promoter controlled oncolytic adenoviruses for killing of CD44+CD24-/low breast cancer cells. Cancer Res. 2008; 68: 5533-9.
Sala G, Dituri F, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M, Lattanzio R, Piantelli M, Iacobelli S, Broggini M, Falasca M: Phospholipase C gamma1 is required for metastasis development and progression. Cancer Res. 2008; 68: 10187-10196.
Sarkioja M, Pesonen S, Raki M, Hakkarainen T, Salo J, Kanerva A & Hemminki A. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther. 2008;15: 921-9.
Krcova Z, Ehrmann J, Krejci V, Eliopoulos A, Kolar Z. Tpl-2/cot and cox-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152: 21-5.
Sarkioja M, Eriksson M, Ristimäki A, Desmond RA, Hakkarainen T, Kanerva A, Hemminki A. The cyclo-oxygenase 2 promoter is induced in non-target cells following adenovirus infection, but an AU-rich 3' UTR destabilization element can increase specificity. J Gene Med. 2008; 10:744-53.
Raki M, Sarkioja M, Desmond RA, Chen D-T, Hemminki A and Kanerva A. Oncolytic adenovirus Ad5/3-?24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol, 2008;108:166-72.
Ribacka C and Hemminki A. Virotherapy as an approach against cancer stem cells. Curr Gene Ther. 2008;8:88-96.
 
CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
(Read More... | Score: 0)

About Us Content : Contact Us
Posted by admin on Monday, May 07 @ 17:22:55 EEST (2191 reads)

 
Aristides Eliopoulos
Aristides Eliopoulos, PhD, Co-ordinator

E-mail apotherapyfp6@yahoo.gr
Phone +30.2810.39.4565 (Office)
+30.2810.39.4819 (Lab)
Fax +30.2810.39.4565
+30.2810.39.4530
Address Αristides Eliopoulos
Associate Professor of Molecular and Cellular Biology
Molecular and Cellular Biology Laboratory
Basic Sciences Division, Rm 2B-12
University of Crete Medical School
PO BOX 2208
71003 Heraklion Crete
Greece.
CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
(Read More... | Score: 0)

About Us Content : Consortium Description
Posted by admin on Monday, May 07 @ 17:20:57 EEST (2150 reads)

 
The Apotherapy consortium possesses a blend of academic specialists and SME with complementary expertise on molecular and cellular biology, molecular medicine, cancer immunotherapy and biomaterial technology. The tasks assigned to the participants aim at maximizing the use of individual expertise and resources for the benefit of the joined research. For more information about the consortium partners, please click follow this link.


CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
(Read More... | Score: 0)

About Us Content : Management
Posted by admin on Monday, May 07 @ 17:19:14 EEST (1950 reads)

 
Co-ordinator
The University of Crete is the Co-ordinator of Apotherapy.
Associate Professor Aristides Eliopoulos represents the University of Crete, as the overall Program Director.

Steering Committee
The Steering Committee represents the decision-making body of Apotherapy. It is comprised of one representative from each of the 7 partners. The Steering Committee monitors and advises upon the general scientific, strategic and financial progress of Apotherapy. It is supported in its task by the Gender Issues advisor, the Ethical & Safety issues advisor and by an External Scientific Advisory Board.

External Scientific Advisory Board.
The External Scientific Advisory Board is a panel of two external experts established to independently evaluate the progress and advise the Apotherapy Steering Committee on the research strategy of the project.
CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
(Read More... | Score: 0)

About Us Content : Research Partners
Posted by admin on Monday, May 07 @ 17:16:44 EEST (4943 reads)

 
Partner 1: University of Crete Medical School, Greece - Coordinator

Aristides Eliopoulos, PhD

Aristides Eliopoulos, PhD
Associate Professor

Email......: eliopag@med.uoc.gr
Web Site: http://mcb.med.uoc.gr


Working at the interface of basic and applied molecular biology, the Eliopoulos laboratory at the University of Crete Medical School aims to understand the mechanisms of signal transduction in carcinogenesis and to utilise this knowledge for the development of more efficient therapies for cancer.  A major focus of the team’s work is the CD40 pathway in solid tumours. The lab is actively pursuing the characterisation of the molecular mechanisms of CD40-induced apoptosis and signal transduction in carcinomas using a combination of yeast-2-hybrid, proteomic and microarray technologies and the development of novel tools for the delivery of CD40L to cancer cells.


 
Partner 2: Queen Mary & Westfield College

Marco Falasca, PhD
Marco Falasca, PhD
Professor

Email......: m.falasca@qmul.ac.uk
Web Site: http://www.icms.qmul.ac.uk/


The laboratory of Marco Falasca at the Department of Medicine, "Queen
Mary & Westfield College" has an established interest in the field of signal transduction and phosphoinositide metabolism. This lab is actively studying the role of PI 3-kinases in intracellular signalling, diabetes and cancer. A major effort in the Falasca laboratory is channelled towards the development of specific inhibitors of PI3-K-dependent pathways as novel cancer therapeutics.

 
Partner 3: Istituto Mario Negri, Italy

Massimo Broggini, PhD
Massimo Broggini, PhD
Group leader

Email......: broggini@marionegri.it
Web Site: http://www.marionegri.it/



The laboratory of Molecular Pharmacology at the Mario Megri Institute of Milan, headed by Massimo Broggini, is involved in the study of the molecular determinants of cellular response to anticancer agents. The lab is actively studying the p53 family of tumor suppressor genes (including p63 and p73) as well as proteins participating in cell cycle checkpoints such as CHK1 and CHK2. Lab activities include the generation of new model systems to study the activity in vitro and in vivo of novel targeted drugs, particularly those directed against signal transduction pathways known to be altered in human cancer (such as the PI3K-akt-mTOR pathway). A major focus of the Broggini team is the molecular characterisation of human ovarian tumors using both genetic and transcriptomic analysis, as well as the isolation and characterisation of ovarian cancer stem cells.

 
Partner 4: University of Helsinki, Finland

Akseli Hemminki, MD, PhD
Akseli Hemminki, MD, PhD
Associate Professor

Email......: akseli.hemminki@helsinki.fi
Web Site: http://www.hi.helsinki.fi/cgtg


The Cancer Gene Therapy Group headed by Akseli Hemminki at the University of Helsinki is actively pursuing the development of strategies to improve systemic delivery of biological therapies for the treatment of cancer. The translational program of the Hemminki laboratory involves evaluation of the activity and mechanism of action of oncolytic adenoviruses, human mesenchymal stem cell carriers and the development of multimodal approaches for the targeted delivery of therapeutic molecules to cancer cells. This team is also involved in clinical trials in patients with advanced cancers refractory to existing treatments.

 
Partner 5: Univerzita Palackeho v Olomouci, Czech Republic

Jiri Ehrmann, MD, PhD
Jiri Ehrmann, MD, PhD
Associate Professor

Email......: cz953006@tiscali.cz
Web Site: http://lmp.upol.cz



The Laboratory of Molecular Pathology, headed by Jiri Ehrmann, operates within the Centre of Molecular Biology and Medicine of Palacky University in Olomouc. Research activities of the laboratory are primarily oriented to the improvement of diagnostics in oncology. The laboratory is well equipped for the automatic, computerised quantitative evaluation of histology slides. On-going projects in the Ehrmann laboratory include the evaluation of the expression and role of proteins regulating the PI3 kinase signaling pathway in glioblastoma and melanoma.

 
Partner 6: University of Uppsala, Sweden

Angelica Loskog, PhD
Angelica Loskog, PhD
Group leader

Email......: angelica.Loskog@klinimm.uu.se
Web Site: http://www.klinimm.uu.se


The Loskog laboratory at the Clinical Immunology Division of Uppsala University has a long term interest in developing CD40 ligand gene therapy for cancer. The CD40 ligand is not only an inducer of apoptosis but also a potent stimulator of the immune system. A major focus of the lab is the evaluation of the immunostimulatory capacity of CD40L in experimental bladder as well as prostate cancer. In in vivo models of bladder cancer, CD40 ligand-based gene therapy has a major impact on reducing tumor growth and the Loskog team is actively pursuing the application of the new therapy to patients in a clinical phase I/II trial.

 
Partner 7: Novosom AG, Germany

Steffen Panzner, PhD
Steffen Panzner, PhD
CSO

Email......: Steffen.Panzner@novosom.com
Web Site: http://www.novosom.com


NOVOSOM AG is a drug delivery company that has developed a unique platform technology for the effective and efficient delivery of oligonucleotides (e.g. antisense, siRNA and decoys) into living cells. Novosom's patented fully charged reversible liposomes (SMARTICLES) are capable of encapsulating large quantities of cargo, remain stable under physiological conditions, and then effectively deliver their payload to targeted delivery sites. Novosom was founded in 1999 by Dr. Steffen Panzner, an expert on the transport of protein molecules through the cell membrane. The company collaborates with a number of leading pharmaceutical companies to develop a range of therapeutic products addressing inflammation, oncology and liver disease. In addition, Novosom also has its own proprietary portfolio of therapeutic agents addressing autoimmune diseases. The lead program is an antisense product targeting CD40, a unique target applicable to a wide range of health problems, from inflammation and autoimmune diseases to oncology. This SMARTICLES-assisted antisense product is currently in preclinical development, where it has demonstrated superior efficacy to TNF antibodies.



CD40, cancer, therapy, PI3 kinase, immunotherapy, gene therapy, signaling, European Commission Program, FP6, Virtual Medical Lab, Faculty of Medicine, University of Crete
(Read More... | Score: 0)

Visitors:
Designed by: George Savakis for Virtual Medical Lab (Faculty of Medicine - Univercity of Crete)